The nanovesicles extracted from the plant and herbal decoctions are identified as a new class of nanomedicine. They are involved in interspecies chemical communication across the plant and animal kingdoms and display a therapeutic potential against a variety of diseases. Herein, we review the recent progress made in the medical applications of plant-derived nanovesicles in the aspects of anti-inflammation, anti-cancer, tissue regeneration, and modulating commensal microbiota. We further summarize the cellular and molecular mechanisms underlying the physiological functions of plant-derived nanovesicles. Overall, plant-derived nanovesicles provide an alternative to conventional synthetic drugs and present exciting opportunities for future research on disease therapy.

Natural extracellular vesicles (EVs) play important roles in many life processes such as in the intermolecular transfer of substances and genetic information exchanges. Investigating the origins and working mechanisms of natural EVs may provide an understanding of life activities, especially regarding the occurrence and development of diseases. Additionally, due to their vesicular structure, EVs (in small molecules, nucleic acids, proteins, etc.) could act as efficient drug-delivery carriers. Herein, we describe the sources and biological functions of various EVs, summarize the roles of EVs in disease diagnosis and treatment, and review the application of EVs as drug-delivery carriers. We also assess the challenges and perspectives of EVs in biomedical applications.

Substantial controversies exist in the exploration of the molecular mechanism of heart failure (HF) and pose challenges to the diagnosis of HF and the discovery of specific drugs for the treatment. Recently, cardiac transthyretin (TTR) amyloidosis is becoming recognized as one of major causes of underdiagnosed HF. The investigation and modulation of TTR misfolding and amyloidal aggregation open up a new revenue to reveal the molecular mechanisms of HF and provide new possibilities for the treatment of HF. The aim of this review is to briefly introduce the recent advances in the study of TTR native and misfolding structures, discuss the correlation between the genotype and phenotype of cardiac TTR amyloidosis, and summarize the therapeutic applications of TTR structural stabilizers in the treatment of TTR amyloidosis-associated HF.

New molecular entities identified by high-throughput screening methods are often poorly watersoluble and thus not easily absorbed in the gastrointestinal tract, due to limitations of dissolution and solubility. There are a variety of approaches to enhancing the drug dissolution and solubility. Particle size reduction is one of these approaches that have been demonstrated as an effective option. Reducing particle size and distribution range increases surface area and speeds up dissolution, thereby facilitating drug absorption. New technologies for obtaining particles in the nanoscale range are being developed [1]. Even so, the ability to control the particles in nanoscale has only recently become part of drug research and development, and much excitement has centered on these technologies' applications for drug delivery [2-4].

No abstract